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ABSTRACT 
 
Epidemiological studies demonstrate that in utero growth restriction and low birth weight are 
associated with impaired lung function and increased respiratory morbidity from infancy, throughout 
childhood and into adulthood.  Chronic restriction of nutrients and/or oxygen during late pregnancy 
causes abnormalities in the airways and lungs of off-spring, including fewer numbers of enlarged 
alveoli with thicker septal walls and basement membranes.  The structural abnormalities and impaired 
lung function seen soon after birth persist or even progress with age.  These changes are likely to 
cause lung symptomology through life and hasten lung aging. 
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Introduction (heading level A) 
 
Next to preterm delivery, intrauterine growth restriction (IUGR) is one of the most important causes of 
perinatal morbidity and mortality1.  In its simplest form, IUGR occurs when the growth restriction is 
pathologic (ie not constitutional), indicating that the fetus has failed to achieve its full growth potential1.  
Most commonly, IUGR results in an infant that is small for gestational age (SGA) with a birth weight 
less than the 10th centile at birth.  However, as birth weight for any given gestation is largely normally 
distributed, an infant can be SGA without also having IUGR, whilst a small number of IUGR infants 
may have birth weights above the 10th centile, and therefore not be classified as SGA.  The term low 
birth weight (LBW), which refers to any infant with a birth weight less than 2500 g, is often used 
erroneously as a proxy for IUGR as this classification does not adjust for maturation and is 
predominantly populated by infants with appropriate growth for gestation.  The confusion between 
these three terms confounds the interpretation of the literature.  The calculation of customised centile 
calculators that consider maternal height, weight, ethnicity and parity and the fetal sex (eg 
http://www.gestation.net/birth weight_centiles/birth weight_centiles.htm)2, can improve distinction of 
true IUGR from the constitutionally small infant. 
 
IUGR is often described as symmetric or asymmetric; whereas the whole body of an infant with 
symmetric IUGR is proportionately small, the infant with asymmetric IUGR preserves growth of critical 
organs, such as the brain and the heart, at the expense of liver, gut and fat.  Asymmetric IUGR 
implies impaired nutrition and affected infants have substantially lower centiles for weight, length and 
body mass index compared to the proportions of the head.  However, the distinction between 
asymmetric and symmetric IUGR may be less clear as arguments that symmetric IUGR represents 
both an early3 and late form of asymmetric IUGR are proposed.  The etiologic basis of IUGR may 
have maternal, placental, fetal or environmental origins (or a combination of any of these), as detailed 
in Figure 1.  Approximately 80-90% of all cases of IUGR amenable to preventive and therapeutic 
management involve impaired transplacental supply of oxygen and nutrients to the fetus4.  Pregnancy 
induced hypertension and its associated pathological uteroplacental circulation is the single most 
contributory factor to the development of IUGR3, whereas maternal smoking accounts for up to 40% 
of IUGR in developed countries5. 
  
Interest in the long term effects of IUGR has gained momentum in recent years: signals related to 
poor placental nutrient transfer during critical periods of fetal development may promote adaptations 
to reduced nutrient transfer that are beneficial in the short term but which may lead to alterations of 
structure or function with adverse long term consequences.  This process of ‘programming’6 is 
recognised as an important means by which perinatal events and the in utero environment contribute 
to disease susceptibility in later life. 
 
Lung development occurs in several distinct stages: embryonic, pseudoglandular, canalicular, 
saccular and alveolar phases7.  Impaired fetal nutrient and oxygen availability can impact on any of 
these phases, potentially affecting long term lung function and respiratory morbidity.  Placental 
insufficiency primarily occurs in late pregnancy in parallel with acinar and alveolar development: IUGR 
will thus most likely affect the structure and function of the distal lung. 
 
This review examines the effects of nutritional and oxygen restriction on lung development in utero.  It 
considers epidemiological evidence suggesting changes in lung development not only impact on lung 
function and respiratory disease in early life, but also cause effects into late adulthood.  Data from in 
vivo animal models support and explain the observational studies. 
 
Effects of IUGR on Lung Development (heading level A) 
 
Much of our understanding of the effects of IUGR on lung development has arisen from studies using 
animal models.  Most animal models of IUGR have restricted fetal growth using a nutritional approach 
(limitation of maternal energy and/or protein intake), interference with placental function and uterine 
blood flow (embolectomy), or placental insufficiency resulting from pre-conception carunclectomy, 
arterial ligation or chronic hypoxia8.  Other models have included exposure to tobacco smoke, late-
gestation ischemia/reperfusion, partial nephrectomy, and repeat antenatal corticosteroids8.  The 
pathophysiology and phenotype of the abnormalities in lung development resulting from these insults 
may vary according to species, timing, chronicity and intensity of the relevant exposure/insult, as well 
as analytical techniques9.  Nonetheless, these studies largely confirm that normal lung development is 
critically dependent on the presence of appropriate oxygen tensions and nutrition10 and that IUGR is 
associated with persisting or developing abnormalities of structure and function in both the airways 
and parenchyma. 
 
Lung Parenchyma (heading level B) 
 
Impairment of fetal nutrition and oxygenation, as frequently occurs in association with IUGR, has 
wide-ranging effects on cellular and molecular events in the developing lung.  These effects include 
reduced surfactant content/activity11, 12, impaired Type II alveolar cell maturation13, reduced alveolar 
cell formation9, 14, diminished alveolar surface area, thickened alveolar walls and air-blood barriers15, 
16, as well as an overall reduction in lung weight, protein and DNA content17. 
 
Reduction in lung DNA content and impaired alveolarisation may arise in part from the diminished 
fetal breathing movements that are associated with IUGR given the known role of these breathing 
movements in maintaining fetal lung expansion and lung growth and development14.  The reduced 
number of alveoli associated with IUGR at birth persists into adulthood, with no evidence of catch up 
in mature sheep14, or rats18.  
 
Prepubertal and adult IUGR animals have increased alveolar size14, 19, caused by enlargement of the 
existing airspaces.  This increase in alveolar volume may be associated with the development of 
emphysema14 and early lung aging.  Although emphysema may arise from abnormal elastin 
expression and deposition, this remains uncertain:  Whereas some have found elastin expression and 
deposition of elastic fibre is reduced in the IUGR rat lung, associated with increased static lung 
compliance at maturity16, 20, Cock found no evidence of similar alterations in elastin in newborn, early 
weanling or adult sheep17.   
  
A study using umbilical-placental embolisation in late gestation, to coincide with saccular and alveolar 
stages of lung development, examined the effects of IUGR in pre-pubertal sheep at 8 weeks19: 
compared to controls, IUGR sheep had fewer alveoli, thicker intra-alveolar septa and persistent 
thickening of the basement membrane. Such changes that are likely to impair gas exchange and alter 
the mechanical properties of the lungs.  It is unknown whether antenatal glucocorticoids rescue this 
pulmonary dysmaturation in the IUGR fetus21.  The abnormal pulmonary development was more 
prominent at 8 weeks than near term, indicating that not only do the lung effects of IUGR persist, but 
they become worse with age.  In a follow-up study into adulthood14, the IUGR group had more 
pronounced abnormalities than at 8 weeks.  Comparisons of septal wall thickness at birth19, 8 weeks19 
and 2 years14, indicate that most changes occurred postnatally due to an accumulation of extracellular 
matrix.  Similar septal wall thickening has been described in mature rats whose mothers were 
nutritionally restricted in pregnancy18.  The reason for the accumulation of extracellular matrix in the 
alveolar septa, and also in the thickened basement membrane, is unknown but several hypotheses 
have been advanced:  The mild neonatal hypoxia associated with IUGR may exert a persistent 
alteration in the metabolic processes within the pulmonary cells; alternatively, increased alveolar wall 
tension during tidal breathing, due to reduced alveoli numbers, may cause an adaptive response of 
extracellular matrix deposition.  Additionally, the increased thickness and cellularity of the pulmonary 
mesenchyme commonly associated with IUGR may result from the increased presence of insulin-like 
growth factor 1 (IGF1)22.  Through binding to its specific tyrosine kinase IGF-1 receptor (IGF1R), IGF1 
initiates intracellular signalling pathways including the Akt (protein kinase B) signalling pathway which 
promotes cell growth and differentiation and inhibits programmed cell death.  Whereas in other 
tissues this process may promote accelerated growth, in the developing lung it represents a 
maladaptive response to the low placental substrate supply.  The transcription factor p53 also has a 
pivotal role in cellular responses to stress, lung mesenchymal thinning via apoptosis, regulation of cell 
cycles and angiogenesis.  The active (phosphorylated) form of p53 (serine-15P) was decreased in the 
distal air space mesenchyme of IUGR rat lungs16.  Messenger RNA of downstream targets of p53 
involved in apoptosis (Bax, Apaf), growth arrest (Gadd45) and angiogenesis (Tsp-1) were decreased 
whilst mRNA for an anti-apoptotic gene normally downregulated by p53 (Bcl-2) was increased.  
 
The effects of IUGR on pulmonary development may be partly mediated by epigenetic mechanisms.  
Epigenetic modifications affect developmental processes by altering gene expression patterns of 
target genes.  In rats, IUGR decreases the transcription factor peroxisome proliferator activated 
receptor gamma (PPARγ), with an associated decrease in a PPARγ downstream target the histone 
methyltransferase enzyme, Setd8, and PPARγ specific histone methylation23.  These changes are 
ameliorated by maternal docosahexaenoic acid (DHA) supplementation; maternal DHA is known to be 
low in pregnancies complicated by IUGR23.  Together, these data suggest a role for PPARγ in IUGR-
induced epigenetic changes in the lung during development and a novel benefit of maternal DHA 
supplementation. 
 
Airways (heading level B) 
 
There are few data concerning the long term effects of IUGR on airway development.  Systematic 
evaluation of airway samples from generation 0 (trachea) to generation 8 (smaller conducting bronchi) 
in sheep with IUGR following late (80% of gestation) umbilical-placental embolization showed no 
effect of IUGR on smooth muscle content but the IUGR group had thinner walls of the larger airways 
with reduced cartilage at birth, suggestive of more collapsible airways24.  However, by 8 weeks after 
birth the airway morphometry was no different to the control group, although the number of bronchial 
submucosal gland profiles was reduced and epithelial mucin area increased in the IUGR group25.  
Tracheas of IUGR fetuses at near term also have thinner mucosal and submucosal layers, in addition 
to decreased epithelial ciliation and decreased mucosal folding26.  
 
Vasculature (heading level B) 
 
An increase in the thickness of the air blood barrier is evident in term gestation lambs born after 
umbilico-placental embolisation27.  Although abnormal pulmonary vascular development and function 
may in part explain increased oxygen requirements and bronchopulmonary dysplasia incidence in 
IUGR preterm infants, there are few studies that have explored this aspect of cardiopulmonary 
development in IUGR fetuses.  A recent investigation showed that pulmonary artery endothelial cells 
from fetal sheep with IUGR due to chronic placental insufficiency have diminished in vitro function and 
reduced signalling through the Akt/eNOS pathway as well as decreased density of the pulmonary 
vessels28.  These data are highly relevant as impaired pulmonary vascular development impedes 
alveolarisation. 
   
Functional consequences of IUGR in the neonatal period (heading level A) 
 
The impact of IUGR on the incidence of neonatal respiratory distress syndrome varies from an 
increased29-31, decreased32 or equivocal33, 34 effect, most probably determined by the duration and 
nature of the insult causing IUGR.  Similar variation in outcome can be observed in animal models. 
 
A key feature of neonatal respiratory distress syndrome is endogenous surfactant deficiency.  Several 
studies showed abnormalities of the surfactant system.  In human infants, placental insufficiency is 
associated with increased lecithin/sphingomyelin ratios in the amniotic fluid, suggestive of accelerated 
lung maturation35, contrasting with lower saturated phosphatidylcholine content of the lungs of 
newborn rat pups11 and guinea pigs12, 36 born to undernourished dams.  Whereas surfactant protein 
synthesis was upregulated in fetal sheep after fetal/maternal hypoxia37, 38, reduced surfactant protein 
and mRNA expression is more often reported in IUGR fetal sheep of carunclectomised ewes39 and 
the hypoxic fetal mouse40.  Hypoxia induced by incubation in 15 % O2 from day 15 in fetal chickens 
increased disaturated phospholipids at day 19 compared to controls, whereas more chronic hypoxia 
extending from day 6 of hypoxia resulted in a borderline decrease in desaturated phospholipid 
content41.  Ultimately, therefore, the effect of hypoxia in IUGR on alveolar surfactant production may 
be modulated by gestation, duration and timing of exposure as well as the availability of surfactant 
substrate11. Interestingly, pulmonary vascular endothelial growth factor, which is expressed in alveolar 
type II cells and a stimulant of surfactant synthesis, is also upregulated by acute hypoxia in the fetal 
chicken41 due to upstream regulation by hypoxia-inducible factor 242. This highlights the key role of 
fetal oxygen tension in regulation of the surfactant system.  PPARγ is a further primary driver of 
adipogenic differentiation in the lung. The alterations in lung structure associated with IUGR 
consequent to maternal food restriction are linked to disturbance of PTHrP/PPARγ signaling between 
alveolar epithelium and mesenchyme18 which appears driven by epigenetic mechanisms in a sex-
dependent manner22. 
  
Long term functional and clinical consequences of IUGR in animal models (heading level A) 
 
The longer-term effects of IUGR on respiratory function and morbidity in later life are not yet fully 
understood.  A small number of studies have characterised the changes in lung function into pre-
puberty and adulthood using animal models.   
  
Growth restriction caused by late gestational umbilical-placental embolisation results in persistent 
impairment of pulmonary function43.  Repeated measurements of the sheep in the 8 weeks following 
birth showed that, in comparison to controls, IUGR resulted in increased minute ventilation, 
decreased pulmonary diffusing capacity, decreased functional residual capacity and total lung 
capacity.  Static lung compliance was reduced and chest wall compliance increased in IUGR lambs, 
but the reason for stiffer lungs was unclear and, of note, surfactant production appeared normal43. 
 
Adult rats demonstrate echocardiographic and histological evidence of pulmonary hypertension 
following in utero hypoxia-induced IUGR44.  This model mimics the hypoxic causes of IUGR such as 
smoking or living at altitude, but may not equate to nutritional causes.  Because of the differences 
between human and rat lung development, the effects of hypoxia at different stages of fetal 
development may differ between species. 
 
Long term cardiorespiratory effects of IUGR in humans (heading level A) 
 
Epidemiological evidence (heading level B) 
 
Ecological studies conducted in the 1980s found that regions of the UK with a high rate of death due 
to coronary heart disease also had high infant mortality45; subsequent investigation identified infants 
with the highest rates of death during infancy were those with the lowest birth weights and surviving 
infants born at low birth weight went on to have the highest risk of cardiovascular disease in 
adulthood46.  These findings were closely followed by the discovery that size at one year was a 
significant predictor of death in adulthood from respiratory causes suggesting that growth restriction 
early in life adversely impacts upon respiratory health47.  Numerous epidemiological studies have 
been conducted with the aims of clarifying the long term respiratory consequences of IUGR. Although 
observational studies are unable to categorically identify individuals whose growth is restricted, in 
many cases low birth weight has been used somewhat imprecisely, as a crude proxy for IUGR. 
Impaired prenatal growth is increasingly believed to be associated with impaired respiratory function 
and poor respiratory health not only immediately after birth but throughout childhood and into 
adulthood48. 
 
Consequences of IUGR for childhood and adult lung function (heading level C) 
 
Observational studies show that within a group of term babies of normal average birth weight, forced 
expiratory flow decreases with decreasing birth weight49 and that respiratory morbidity in early 
childhood is associated with lower infant lung function 50.  These findings suggest that an in utero 
environment less conducive to somatic growth also impairs lung development, with consequences for 
early respiratory health.  Impairment is more pronounced in children who gain weight rapidly after 
birth49, 51, hence rapid postnatal weight gain following low birth weight may indicate mismatch between 
pre- and postnatal nutrient supply and thus identify infants subjected to fetal growth restriction.  
 
Impairments of lung function, specifically reduced expiratory flows52, 53 and hyperreactive airways54, 
are found beyond the period of infancy in children who were of low weight at birth.  Early studies 
generally compared children selected for low absolute birth weight to controls of average birth 
weight53, although some attempted to control for maturational effects by considering term infants 
separately from preterms54 or using weight for gestation z-scores52, and others attempted to identify 
growth restricted fetuses by assessing lung function in children born at significantly lighter birth weight 
than their co-twin52.  More recent studies considered the issue of fetal growth restriction across the full 
range of birth weights. For example, a large study of more than 2000 children aged 5-11 years 
demonstrated that those born at lower weight adjusted using a regression method for gestational age 
had lower than expected values of FEV1, regardless of whether they were born at term or preterm55.  
Persistently impaired lung function following fetal growth restriction is unsurprising given prospective 
cohort studies demonstrated lung function to ‘track’ in individuals followed up from infancy through 
childhood56, 57 and into later life57. 
 
A large, early epidemiological study of British men aged 59-70 years demonstrated reduced FEV1 
standardised with respect to age and height in those born with lower birth weights compared to others 
in this cohort47. Similar results were found in a survey of men and women from southern India58.  
Although in many historical studies gestational age is uncertain, prematurity is unlikely to confound 
these results as survival following preterm birth was low at the time these individuals were born58.  
Moreover, studies in which the association between birth weight and lung function were adjusted for 
gestational age and maternal factors (including height, weight and parity) suggest that growth 
restriction is responsible for this effect59.  More recently, birth weight was positively associated with 
both FVC and FEV1 in a large prospective population-based cohort of men and women aged 31 years 
in Finland.  These findings were independent of adult height, gestation, maternal smoking and 
respiratory disease60.  Similarly, a recent meta-analysis of eight studies exploring the relationship 
between LBW and adult lung function reported an increase in FEV1 of 48 mL per kilogram increase in 
birth weight after adjustments for age, smoking, and height61.  However, although reduced lung 
function in adulthood following fetal growth restriction appears a reasonably robust finding, the extent 
to which ‘catch-up’ growth might compensate for the effects of intrauterine adversity is less clear.  
Whilst early infant lung function studies suggest poorer lung function is associated with rapid early 
growth49, 62, other studies provide evidence of compensation for the effects of fetal growth restriction 
upon lung function measured later in life60, 63, 64. 
 
Consequences of IUGR for childhood and adult respiratory morbidity (heading level C) 
 
Many investigators have sought an association between evidence of fetal growth restriction and 
childhood asthma or wheeze, given both the observed association between birth weight and forced 
expiratory flows and the prominence of airways obstruction in these respiratory disorders.  Whilst 
acknowledging that low birth weight is not synonymous with IUGR and epidemiological techniques are 
limited in their ability to determine to what extent each individual has fulfilled their growth potential, 
birth weight is used by many as a proxy for fetal growth to assess long term respiratory morbidity: an 
association between an increased risk of childhood wheeze and lower birth weight65, 66 has been 
found by some, however, others have found an association with higher birth weight67, and some no 
relationship at all54, 68-70.  Although a recent meta-analysis concluded that an increased risk of asthma 
in childhood or early adult life is associated with higher birth weight71, the conclusions of individual 
studies differed considerably on this point.  Some misclassification of outcome may have occurred in 
this analysis as wheeze outcomes measured at different ages were combined; this may not be valid 
given that the prevalence of the various wheeze phenotypes varies with age72.  Moreover, this meta-
analysis included only those studies dichotomising birth weight as above average or average and did 
not consider the full range of birth weights. 
 
The clinical symptoms recognised as asthma probably arise from a number of related syndromes 
rather than a single illness72, 73.  Although there is considerable overlap between the different 
‘wheezing syndromes’, the early life histories of those children whose symptoms are limited to early 
childhood may differ from those who suffer persistent wheeze, and in particular from those suffering 
wheeze in association with atopy.  The health outcomes of infants demonstrating disproportionate 
growth support a role for restricted fetal growth in the development of an atopic predisposition or 
symptoms of atopic disease.  For example, infants with larger head circumference at birth are at 
increased risk of elevated serum total IgE67,74 and asthma in childhood75 compared to children with 
smaller head circumferences.  Disproportionate head growth may reflect prioritisation of the growth of 
the brain over that of immune tissue such as the thymus under conditions where the nutritional needs 
of the fetus cannot be met.  These findings are not without controversy.  The proposed association 
between disproportionate growth and atopic disease is an inconsistent finding of all epidemiological 
studies; some studies found atopy is associated with higher birth weight76, 77 and length67.  Moreover, 
there is evidence to contradict the proposal that larger head size is associated with decreased thymic 
volume78. 
  
Poor lung function in adulthood is a consistent independent predictor of all-cause mortality and deaths 
due to respiratory and cardiovascular disease79, 80.  This suggests fetal growth restriction may have 
lasting clinical effects with important public health implications.  Studies of young adult conscripts81, 82 
demonstrated an inverse relationship between asthma risk and birth weight and this conclusion was 
recently confirmed by follow-up of individuals from the 1970 British national birth cohort83 and a large 
Swedish twin study84.  Lower weight at birth and in early infancy is also associated with a higher 
standardised mortality from chronic obstructive pulmonary disease47.  These findings have led to the 
proposal that impaired lung growth may lead to chronic airflow obstruction in late adult life through a 
failure to obtain maximal lung function potential as a young adult, even if the subsequent rate of 
decline with age is normal85, 86.  
 There is also evidence that IUGR is associated with abnormal pulmonary vasculature.  Pulmonary 
arterial branch stenosis is generally considered a transient phenomenon in neonates and young 
infants.  It does however persist beyond a year in a minority of cases, and this persistence is related 
to IUGR but not prematurity87.  IUGR, as measured by ponderal index for gestational age, is also 
associated with an increased incidence and severity of persistent pulmonary hypertension of the 
newborn88. 
  
In summary, in vivo models of IUGR support the epidemiological findings that fetuses subjected to 
impaired nutrition and oxygen have impaired morphological and functional features of lung and 
pulmonary vascular development.  Importantly these changes persist or even develop with increasing 
age. 
 
Conclusions (heading level A) 
 
Epidemiological studies using low birth weight as a proxy for IUGR, demonstrate associations with 
reduced infant lung function and early respiratory morbidity, and also reveal that impaired lung 
function and respiratory disease persist into adulthood.  IUGR can be caused by maternal, placental 
or fetal causes, and it is difficult in epidemiological studies to tease out the relative factors (such as 
tobacco exposure, infections or maternal vascular disease) and whether these are having a direct or 
indirect (affecting the nutrient supply) effect on lung development.  Additionally, uncertainties about 
gestational age at birth confound many, but not all epidemiological studies and future studies should 
aim to separate maturation from IUGR by analysing gestational age and birth weight z-score rather 
than birth weight.  
 
In vivo models of maternal nutrient restriction in later pregnancy have provided important insights into 
the structural and functional implications of IUGR.  These studies show that impaired nutrient and 
oxygen availability to the fetus causes microscopic structural changes which are apparent not only 
soon after birth, but persist in mature lungs.  Fetal nutrition was restricted during the alveolar phase of 
lung development in many studies.  This coincides with the timing when placental insufficiency and 
other causes of IUGR are most likely to occur.  The impact of variations in the timing and severity of 
restriction still need further elucidation.  
PRACTICE POINTS 
 
 Compromise during pregnancy has life-long implications for respiratory health, morbidity and 
mortality in the off-spring.  
 Prevention of fetal compromise through careful monitoring and intervention during pregnancy. 
 Avoidance of preventable causes of IUGR, in particular education and assistance to avoid tobacco 
smoking in pregnancy. 
 Future epidemiological analyses need to carefully separate contribution of gestation and intrauterine 
growth restriction by using birth weight Z score rather than birth weight as the indicator of 
intrauterine nutrition. 
 
RESEARCH DIRECTIONS  
 
 Development of effective methods to prevent mothers smoking in pregnancy. 
 A greater understanding of the changes in lung development that are caused by IUGR may lead to 
further research to investigate ways of blocking the abnormal development or enhancing normal 
lung development. 
 Evaluation of the long term effects of IUGR on surfactant production, innate immunity of the lung, 
mucins, and ciliary function, and function of the respiratory musculature.  
 A better understanding of how different causes, timing and duration of IUGR impact on lung 
development. 
 Improved detection of fetal compromise during pregnancy, and methods to intervene. 
 Assessment of the effect of fetal lung maturational treatments (such as glucocorticoids) on the 
viability and long term cardiorespiratory outcomes of the IUGR infant. 
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Figure 1 -  Causes of Intrauterine Growth Restriction: Maternal, fetal, placental and environmental 
(outside circle) factors that contribute to development of intrauterine growth restriction  
